O&M awarded £7m of Glaxo SmithKline business in the UK

Ogilvy & Mather has won at least an additional £7 million in

Glaxo SmithKline business in the UK from the rival roster agencies Grey

Worldwide and McCann-Erickson.



O&M has taken the Macleans toothpaste account, worth more than £4

million in the UK, from Grey. It has also taken the Zantac and Zovirax

cold sore cream work from McCann in all countries that it is sold over

the counter.



The account is worth £2 million in the UK.



Glaxo SmithKline has also unveiled plans to enter the premium fruit

juice market with a new brand, Plenty, to be launched later this year

with creative through Grey.



The roster realignment follows the merger of SmithKline Beecham and

Glaxo Wellcome at the end of last year and the subsequent acquisition of

Block Drug. The changes come into effect from January 2002.



A press release said: "Grey Worldwide will be responsible for all former

Block Drug Sensodyne and Denture Care accounts with the exception of the

UK and Japan where the incumbent agencies, PTK and Asatsu DK

respectively, will be retained.



"Ogilvy & Mather will be appointed to handle the Zovirax, Zantac,

Beconase and Eumovate brands in all countries where these products are

marketed in over-the-counter form. O&M will also gain two oral care

assignments: Macleans in the UK and Iodosan in Italy."



Over-the-counter medicine accounts in the US will be consolidated across

four agencies - Grey, Publicis, Arnold McGrath and Creative Advertising

Services. The Phazyme brand will transfer from Grey to Publicis, Balmex

will move from Grey to CAS and Citrucel will move from O&M to Arnold

McGrath.